CN112138022A - 具有角膜修护功能的眼用产品 - Google Patents
具有角膜修护功能的眼用产品 Download PDFInfo
- Publication number
- CN112138022A CN112138022A CN202010240704.1A CN202010240704A CN112138022A CN 112138022 A CN112138022 A CN 112138022A CN 202010240704 A CN202010240704 A CN 202010240704A CN 112138022 A CN112138022 A CN 112138022A
- Authority
- CN
- China
- Prior art keywords
- ophthalmic
- gold nanoparticles
- product
- corneal
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940023490 ophthalmic product Drugs 0.000 title claims abstract description 54
- 210000004087 cornea Anatomy 0.000 title abstract description 18
- 239000010931 gold Substances 0.000 claims abstract description 72
- 229910052737 gold Inorganic materials 0.000 claims abstract description 72
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 65
- 239000002105 nanoparticle Substances 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 230000008439 repair process Effects 0.000 claims abstract description 38
- 239000002245 particle Substances 0.000 claims abstract description 17
- 239000004615 ingredient Substances 0.000 claims abstract description 11
- -1 monophenol compound Chemical class 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 125000000524 functional group Chemical group 0.000 claims description 9
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 150000004804 polysaccharides Chemical class 0.000 claims description 7
- 150000003573 thiols Chemical class 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 235000019136 lipoic acid Nutrition 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- 229960002663 thioctic acid Drugs 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- IKALZAKZWHFNIC-JIZZDEOASA-L dipotassium;(2s)-2-aminobutanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O IKALZAKZWHFNIC-JIZZDEOASA-L 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 229940097043 glucuronic acid Drugs 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000003716 rejuvenation Effects 0.000 claims description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 26
- 210000000695 crystalline len Anatomy 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000004806 packaging method and process Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 7
- 208000028006 Corneal injury Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229920003169 water-soluble polymer Polymers 0.000 description 5
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 206010023644 Lacrimation increased Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- 229940093265 berberine Drugs 0.000 description 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 210000000399 corneal endothelial cell Anatomy 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004317 lacrimation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 229960003101 pranoprofen Drugs 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- NTYZDAJPNNBYED-UHFFFAOYSA-M sodium;2-(2-dodecanoyloxypropanoyloxy)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O NTYZDAJPNNBYED-UHFFFAOYSA-M 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- UDVBTTICUXAATP-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O.CCCCC(N)C(O)=O UDVBTTICUXAATP-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NAUWDZBVOYLSQR-UHFFFAOYSA-N C1(=CC=C2C=CC=CC=C12)S(=O)(=O)O.C1(=CC=C2C=CC=CC=C12)S(=O)(=O)O Chemical compound C1(=CC=C2C=CC=CC=C12)S(=O)(=O)O.C1(=CC=C2C=CC=CC=C12)S(=O)(=O)O NAUWDZBVOYLSQR-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
- G02C7/047—Contact lens fitting; Contact lenses for orthokeratology; Contact lenses for specially shaped corneae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Ceramic Engineering (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Eyeglasses (AREA)
Abstract
本发明涉及一种具有角膜修护功能的眼用产品。所述眼用产品包括眼用组合物,眼用组合物包含多个纳米金颗粒以及至少一种辅助修护成分。纳米金颗粒可作为主要修护成分,纳米金颗粒的有效浓度为0.01ppm至3000ppm,辅助修护成分的含量,以眼用组合物的总量为100wt%计,为大于0且小于20wt%。借此,本发明的眼用产品能增强眼睛各层组织内细胞的保护及修复能力,并能提升隐形眼镜的配戴舒适度。
Description
技术领域
本发明涉及一种眼用产品,特别是涉及一种具有角膜修护功能的眼用产品,例如隐形眼镜相关产品或眼药产品。
背景技术
角膜位于眼球最前端,角膜本身是透明无血管,其营养来源除房水供应外,周边角膜主要依赖角膜缘血管网。角膜具有十分敏感的神经末梢,一旦有外物接触角膜,眼睑便会不由自主地合上以保护眼睛。角膜除了具有保护眼内容物的作用外,又是眼屈光系统的重要组成部分,类似照相机的镜头。
大多数视力不佳的人都有长时间配戴隐形眼镜的习惯,然而长时间配戴隐形眼镜的结果,可能导致角膜发炎、受损;例如,隐形眼镜刮伤角膜,或是隐形眼镜没有做好清洁而导致角膜感染。一般较轻微的角膜受损可以在二十四小时之内自动修复,至于较严重的角膜破裂,则须经过医师诊断后给予适当的治疗。此外,许多上班族因为每天工作需要持续盯着计算机屏幕,时间久了容易让眼睛干涩,此时眼球因为失润度降低,可能会失去天然的保护膜,而增加感染角膜炎的机率。
因此,日常生活中亟需一种创新的眼用产品,来预防和及时而有效的治疗日常角膜损伤。
发明内容
本发明所要解决的技术问题在于,针对现有技术的不足提供一种具有角膜修护功能的眼用产品,其能维持眼睛的健康与舒适。
为了解决上述的技术问题,本发明所采用的其中一技术方案是,提供一种具有角膜修护功能的眼用产品,其包括一眼用组合物,其特征在于,所述眼用组合物包含多个纳米金颗粒以及至少一辅助修护成分,所述纳米金颗粒的有效浓度为0.01ppm至3000ppm,所述辅助修护成分的含量,以所述眼用组合物的总量为100wt%计,为大于0且小于20wt%。
在本发明的一实施例中,所述纳米金颗粒的平均粒径为0.01nm至100 nm,且所述纳米金颗粒的有效浓度为0.05ppm至1600ppm,其中,所述辅助修护成分的含量为0.01wt%至5wt%。
在本发明的一实施例中,所述纳米金颗粒的平均粒径为0.5nm至40nm,且所述纳米金颗粒的有效浓度为1ppm至400ppm,其中,所述辅助修护成分的含量为0.05wt%至3wt%。
在本发明的一实施例中,所述纳米金颗粒的表面修饰有至少一种功能性分子团,所述功能性分子团选自亲水性官能基、含酚基的化合物、多醣类物质、含至少一个NH2基或COOH基的肽类物质及硫醇配体中的至少一种。
在本发明的一实施例中,所述功能性分子团的含量,以眼用组合物的总量为100wt%计,为0.01wt%至5wt%。
在本发明的一实施例中,所述亲水性官能基为OH基、CONH基、CONH2 基或COOH基。
在本发明的一实施例中,所述含酚基的化合物为单酚类化合物、多酚类化合物或黄酮类化合物。
在本发明的一实施例中,所述多醣类物质为醣醛酸、甲基羧酸几丁质、甲基羧酸几丁聚醣、褐藻酸或透明质酸。
在本发明的一实施例中,所述肽类的分子量为300Dalton至300,000 Dalton。
在本发明的一实施例中,所述硫醇配体为硫辛酸或二氢硫辛酸。
在本发明的一实施例中,所述辅助修护成分选自硫酸软骨素、α-硫辛酸、 2-氨基乙磺酸以及L-天门冬氨酸钾中的至少一种。
在本发明的一实施例中,所述眼用组合物的pH值为6至8,且渗透压为 240Osmol/Kg至400Osmol/Kg。
在本发明的一实施例中,所述眼用组合物以溶液、凝胶或软膏的形式存在。
在本发明的一实施例中,所述具有角膜修护功能的眼用产品还包括一传递媒介,用于将所述眼用组合物传递至眼睛。
在本发明的一实施例中,所述传递媒介为一眼用基质或敷料。
在本发明的一实施例中,所述具有角膜修护功能的眼用产品还包括一隐形眼镜镜片,且所述隐形眼镜镜片浸泡于以溶液形式存在的所述眼用组合物中。
为了解决上述的技术问题,本发明所采用的另外一技术方案是,提供一种具有角膜修护功能的眼用产品,其包括一眼用组合物,其特征在于,所述眼用组合物包含多个纳米金颗粒,所述纳米金颗粒的有效浓度为0.01ppm至 3000ppm,所述纳米金颗粒的平均粒径为0.01nm至100nm。
在本发明的一实施例中,所述纳米金颗粒的平均粒径为0.5nm至40nm。
在本发明的一实施例中,所述纳米金颗粒的有效浓度为0.05ppm至1600 ppm。
在本发明的一实施例中,所述纳米金颗粒的平均粒径为0.5nm至40nm,且所述纳米金颗粒的有效浓度为1ppm至400ppm。
本发明的其中一有益效果在于,本发明的具有角膜修护功能的眼用产品,其能通过“眼用组合物包含多个纳米金颗粒以及至少一辅助修护成分,纳米金颗粒的有效浓度为0.01ppm至3000ppm”的技术特征,以达到预防和治疗日常角膜损伤,及减少如疼痛、畏光、流泪、模糊、血管增生等眼睛不适症状。
为使能更进一步了解本发明的特征及技术内容,请参阅以下有关本发明的详细说明与附图,然而所提供的附图仅用于提供参考与说明,并非用来对本发明加以限制。
附图说明
图1为本发明的眼用产品的其中一局部示意图。
图2为本发明的眼用产品的另外一局部示意图。
图3为本发明的眼用产品的另外再一局部示意图。
图4为本发明的眼用产品的一较佳实施方式的立体示意图。
图5为本发明的眼用产品的一较佳实施方式的剖面示意图。
图6为本发明的眼用产品的另一较佳实施方式的使用状态图。
具体实施方式
以下是通过特定的具体实施例来说明本发明所公开有关“具有角膜修护功能的眼用产品”的实施方式,本领域技术人员可由本说明书所公开的内容了解本发明的优点与效果。本发明可通过其他不同的具体实施例加以施行或应用,本说明书中的各项细节也可基于不同观点与应用,在不悖离本发明的构思下进行各种修改与变更。另外,本发明的附图仅为简单示意说明,并非依实际尺寸的描绘,事先声明。以下的实施方式将进一步详细说明本发明的相关技术内容,但所公开的内容并非用以限制本发明的保护范围。
应当可以理解的是,虽然本文中可能会使用到“第一”、“第二”、“第三”等术语来描述各种组件或者信号,但这些组件或者信号不应受这些术语的限制。这些术语主要是用以区分一组件与另一组件,或者一信号与另一信号。另外,本文中所使用的术语“或”,应视实际情况可能包括相关联的列出项目中的任一个或者多个的组合。
除非另外定义,否则本文中使用的所有技术及科学术语,都具有与本领域技术人员通常所理解含义相同的含义。当术语以单数形式出现时,涵盖此术语的复数形式。
除非另有指示,否则本文中提到的所有百分比都为重量百分比。当提供一系列上、下限范围时,涵盖所提到的范围的所有组合,如同明确列出各组合。
为了增强眼睛各层组织内细胞(如角膜细胞)的保护及修复能力,本发明提供一种具有角膜修护功能的眼用产品。本发明的眼用产品包括一眼用组合物,眼用组合物主要包含多个纳米金颗粒以及至少一辅助修护成分;使用时,眼用产品可通过眼用组合物直接或间接接触眼表区域的方式,以将有效量的纳米金颗粒与辅助修护成分传递至眼表区域,而纳米金颗粒与辅助修护成分可以产生角膜修护的协同增效作用。本文中术语“眼表区域”包括角膜、结膜、泪膜及它们相邻或相关的结构。
进一步而言,本发明的眼用产品可为隐形眼镜的相关产品或眼药产品。眼用组合物可以溶液、凝胶或软膏的形式存在,例如可作为隐形眼镜的包装溶液、储存溶液、清洁溶液或养护溶液,或作为眼睛的多功能滴剂或眼药制剂。然而,本发明不以上述所举的例子为限。
在本实施例中,纳米金颗粒的有效浓度可为0.01ppm至3000ppm,较佳为0.05ppm至1600ppm,更佳为1ppm至400ppm;例如,纳米金颗粒的有效浓度可为5ppm、10ppm、15ppm、20ppm、25ppm、50ppm、75ppm、 100ppm、150ppm、200ppm、250ppm、300ppm或350ppm。本文中术语“有效浓度”是指可传递足够量的纳米金颗粒至眼表区域产生有益效果的浓度。
已经发现,纳米金颗粒至少具有抗氧化、抗发炎、抗敏舒缓、修护角膜及抑制血管增生等功能或作用;因此,本发明的眼用产品,其中眼用组合物包含纳米金颗粒,能有效维持眼睛的健康与舒适。
参阅图1及图2所示,眼用组合物包含分散媒介200,而纳米金颗粒100 通过分散媒介200呈分散状态。眼用组合物可以水作为分散媒介200,但不限于此;分散媒介200,以眼用组合物的总量为100wt%计,可为75wt%至 99wt%,较佳为85wt%至99wt%。根据实际应用,如图2所示,可使一些纳米金颗粒100团聚在一起而形成纳米金颗粒团100’。纳米金颗粒100或纳米金颗粒团100’的平均粒径可为0.01nm至100nm,较佳为0.5nm至40nm。
参阅图3所示,根据实际应用,可在纳米金颗粒100或纳米金颗粒团100’的表面修饰有至少一种功能性分子团,即功能性分子团附着于纳米金颗粒 100或纳米金颗粒团100’的表面上,以增加其功能性;功能性分子团可选自亲水性官能基、含酚基的化合物、多醣类物质、含至少一个NH2基或COOH 基的肽类物质及硫醇配体中的至少一种,但不限于此。功能性分子团的含量,以眼用组合物的总量为100wt%计,可为大于0且小于20wt%,较佳为0.01wt%至5wt%,更佳为0.05wt%至3wt%。
值得说明的是,表面修饰有亲水性官能基的纳米金颗粒100或纳米金颗粒团100’,可具有良好的亲水性。表面修饰有含酚基的化合物的纳米金颗粒100或纳米金颗粒团100’,较佳为同时修饰有单酚类、多酚类及黄酮类化合物,可具有调控细胞内谷胱甘肽浓度的功能。表面修饰有多醣类物质的纳米金颗粒100或纳米金颗粒团100’,以及表面修饰有含至少一个NH2基或COOH基的肽类物质的纳米金颗粒100或纳米金颗粒团100’,不仅可以满足生物安全性的要求,还可以提升抗自由基和保湿能力。表面修饰有硫醇配体的纳米金颗粒100或纳米金颗粒团100’,其抗氧化能力可以得到提升。
在本实施例中,亲水性官能基可为OH基、CONH基、CONH2基或COOH 基;多醣类物质可为醣醛酸、甲基羧酸几丁质、甲基羧酸几丁聚醣、褐藻酸或透明质酸;肽类物质的分子量可为300至300,000Dalton(道尔顿);硫醇配体可为含SH基的分子团,例如硫辛酸或二氢硫辛酸。然而,本发明不以上述所举的例子为限。
辅助修护成分的含量,以眼用组合物的总量为100wt%计,可为大于0 且小于20wt%,较佳为0.001wt%至5wt%,更佳为0.005wt%至3wt%;例如,辅助修护成分的含量可为0.01wt%、0.05wt%、0.1wt%、0.2wt%、0.3wt%、 0.4wt%、0.5wt%、0.6wt%、0.7wt%、0.8wt%、0.9wt%、1.0wt%、1.5wt%、 2.0wt%或2.5wt%。
在本实施例中,辅助修护成分可选自硫酸软骨素、α-硫辛酸、2-氨基乙磺酸以及L-天门冬氨酸钾中的至少一种,但不限于此。值得说明的是,这几种物质能促进眼球多层组织的微循环,进而能促进细胞新陈代谢、增加细胞含氧量、滋养眼部等功效,尤其能活化眼角细胞的呼吸,带给眼睛清良舒适的感觉。再者,这几种物质与纳米金成分可以不同的机理协同运作,而产生预想不到的角膜修护效果。
眼用组合物还可包含缓冲剂、表面活性剂、水溶性聚合物、活性药物成分及其他功能性添加剂。缓冲剂可以协助调节眼用组合物的pH值和渗透压,从而眼用组合物可以发挥预期的效果,即对眼睛提供有益效果。眼用组合物的pH值可为6至8,较佳为7至8;眼用组合物的渗透压可为240Osmol/Kg 至400Osmol/Kg,较佳为260Osmol/Kg至340Osmol/Kg。
在本实施例中,缓冲剂可为硼酸盐或磷酸盐缓冲剂;缓冲剂的含量,以眼用组合物的总量为100wt%计,可为大于0且小于5wt%(如0.5wt%、1wt%、 1.5wt%、2wt%、2.5wt%、3wt%、3.5wt%或4wt%)。硼酸盐缓冲剂可包含硼酸、氯化钠及硼酸盐(如四硼酸钠),但不限于此。磷酸盐缓冲剂可包含氯化钠及磷酸盐(如磷酸二氢钠、磷酸氢二钠、磷酸二氢钾及磷酸氢二钾等),但不限于此。
表面活性剂可以清除眼脂,改善视力模糊,且可以更好的发挥纳米金成分的效果;表面活性剂可选自聚山梨醇酯80(TWEEN 80)、磺基丁二酸烷基酯(SBFA 30)、月桂酰乳酰乳酸钠(sodium lauroyl lactylate)、聚氧丙烯二醇 (polyoxypropylene glycol)、聚氧乙烯硬化蓖麻油(polyoxyethylene hardened castor oil)及聚乙烯吡咯啶酮(PVP)中的至少一种,但不限于此。表面活性剂的含量,以眼用组合物的总量为100wt%计,可为0.01wt%至5wt%,较佳为 0.01wt%至3wt%(如0.5wt%、1wt%、1.5wt%、2wt%或2.5wt%)。
水溶性聚合物可以增加眼睛的湿润感;此外,水溶性聚合物可以协助纳米金成分的缓释作用,及延长纳米金成分于眼中的停留时间,以对眼睛提供有益效果。水溶性聚合物选自聚乙二醇(PEG400)、丙烯酸甲酯磷酸胆碱(MPC) 及玻尿酸(hyaluronic acid)中的至少一种,但不限于此。水溶性聚合物的含量,以眼用组合物的总量为100wt%计,可为0.01wt%至5wt%,较佳为0.01wt%至3wt%(如0.5wt%、1wt%、1.5wt%、2wt%或2.5wt%)。
活性药物成分可提供抗发炎、抗敏舒缓作用;活性药物成分可选自普拉洛芬(pranoprofen)、胺基己酸(ε-aminocaproic acid)、尿囊素(allanton)、小蘗碱(berberine)、薁磺酸(azulene sulfonate)、甘草酸(glycyrrhizinate)、色甘酸钠(sodium cromoglycate)及硫酸锌中的至少一种。活性药物成分的含量,以眼用组合物的总量为100wt%计,可为0.001wt%至20wt%(如0.01wt%、0.05wt%、 1wt%、5wt%或10wt%)。在本实施例中,眼用组合物可以0.001wt%至5wt%的普拉洛芬、0.001wt%至5wt%的胺基己酸、0.001wt%至5wt%的尿囊素、 0.001wt%至10wt%的小蘗碱、0.001wt%至10wt%的甘草酸、0.001wt%至 10wt%的色甘酸钠或0.001wt%至10wt%的硫酸辛作为活性药物成分,但不限于此。
功能性添加剂可选自抗菌剂、维生素或其组合,但不限于此。功能性添加剂的含量,以眼用组合物的总量为100wt%计,可为0.01wt%至5wt%。抗菌剂的具体例包括:聚六亚甲基双胍(polyhexamethylene biguanide,PHMB)、聚六亚甲基双胍的水溶性盐、聚胺丙基双胍(polyaminopropyl biguanide,PAPB) 及聚胺丙基双胍的水溶性盐等;维生素的具体例包括:维生素B6(盐酸吡多醇,pyridoxine hydrochloride)、维生素B12(氰钴胺,cyanocobalamin)及维生素E(人工合成的α-生育酚,DL-alpha-tocopherol)。然而,本发明不以上述所举的例子为限。
参阅图4及图5所示,本发明的眼用产品300的其中一较佳实施方式为隐形眼镜产品,其包括:一包装结构310、一眼用组合物的包装溶液320及一隐形眼镜镜片330。包装溶液320与隐形眼镜镜片330一起被密封在包装结构310内,并经过灭菌处理(如:高温或高压灭菌),其中隐形眼镜镜片330 浸泡于包装溶液320中。
进一步而言,包装结构310包括一容器311及一覆片312,容器311用于容置包装溶液320与隐形眼镜镜片330,覆片312可剥离的结合于容器311 上,以将容器311的开口封闭。在本实施例中,容器311的材料可为塑料,且可对隐形眼镜镜片330提供合理程度的保护;覆片312的材料可为金属或塑料;隐形眼镜镜片330的材料可为水胶(hydrogel)或硅水胶(silicone hydrogel),且视需要可含有功能性成分(如蓝光吸收成分或UV吸收成分)。然而,本发明不以上述所举的例子为限。
值得说明的是,在浸泡时包装溶液320中的有益成分会进入隐形眼镜镜片330或附着于隐形眼镜镜片330上;因此,只要戴上隐形眼镜镜片330,有益成分就可以从隐形眼镜镜片330传递至眼表区域,而达到预防和治疗日常角膜损伤,及减少如疼痛、畏光、流泪、模糊、血管增生等眼睛不适症状。
参阅图6所示,本发明的眼用产品400的另外一较佳实施方式为眼药产品,其包括一眼用组合物的眼药制剂410;使用时,眼药制剂410可通过滴眼的方式传递至眼表区域,但不限于此。在其他实施例中,眼药制剂410可通过一传递媒介(如眼用基质或敷料)传递至眼表区域。
评价项目
制造眼用产品:
依表1中列出的几个代表性实施例与比较例的配方制备隐形眼镜包装液,再将多片晶硕公司生产的水胶隐形眼镜分别置于根据实施例的隐形眼镜包装液中,然后进行密封及高温灭菌处理(125℃、30分钟),如此便完成了眼科用品(隐形眼镜产品)的制造。
表1中实施例与比较例的比较,是招募10名临床受测者配戴330隐形眼镜镜片,以问卷收集自觉式评价,评价项目分负面及正面两大部分,并分别于刚戴上隐形眼镜与戴上4小时以上,对每一个评价项目都计算出10名的分数平均值,结果显示于表2。
隐形眼镜为医疗器材,在临床试验前生物兼容性为重要指标,尤其以细胞毒性试验为最初测试指标,因此将表1实施例及比较例分别依据ISO 10993-5:2009进行体外细胞毒性试验,目的为确定测试对象对于细胞株L-929 老鼠纤维母细胞无细胞毒性,测试物分别为隐形眼镜镜片及包装溶液,毒性评估鉴别依据ISO 10993-5:2009Table 1Qualitativemorphological grading of cytotoxicity of extracts分为0-4级:等级0级为无细胞毒性;等级1级为极轻微细胞毒性,细胞变异小于20%;等级2级为轻微细胞毒性,细胞变异小于 50%;等级3级为中度细胞毒性,细胞变异小于70%;等级4级为严重细胞毒性,细胞几乎完全损坏,测试结果显示于表3。
近几年智能型手机与可发出蓝光的LED光源的普及率越来越高,如果长期在室外工作者更无法避免日光直射的蓝光伤害,长期照射蓝光会造成角膜细胞受损甚至于坏死,严重甚至会产生黄斑部病变,造成视力模糊、扭曲、视觉中心暗影,因此若能有效舒缓日常蓝光伤害,使细胞伤害不会持续累积,对于眼部健康十分重要。2017国际眼科杂志提到眼睛细胞内部含有还原型的谷胱甘肽GSH,是一种人体本身存在的抗氧化物,其高浓度存在于晶状体、角膜、视神经,视网膜及睫状体内,它可通过硫醇基与体内的自由基结合转化成容易代谢的酸类物质从而加速自由基的排泄,对不稳定的晶状体蛋白质硫醇基有抑制作用,可抑制白内障的发生及控制角膜,视网膜病变的发展,有益于角膜或晶状体透明性的维持以及组织的再生与修复。因此如果能藉由本发明来蓝光对修护眼表的细胞伤害,进而降低细胞中还原型谷胱甘肽GSH 因蓝光伤害造成的损失,即能有效预防眼疾的发生率,减少蓝光对眼部的累积伤害。
因此本发明比较表1实施例及比较例的角膜细胞修护能力,选用蓝光照射角膜细胞,再加入隐形眼镜镜片,以修护模式定量细胞中GSH的含量,观察细胞伤害程度来做验证,选用的细胞株为牛眼角膜内皮细胞(Bovine corneal endothelial cells)。实验方法为将眼角膜内皮细胞播种于12孔细胞培养板上培养12小时,先以3W蓝光灯泡照射24小时,分别加入表1实验例4与比较例1中的隐形眼镜镜片共同浸泡24小时,检测细胞GSH含量,受伤的细胞 GSH会降低。测试结果显示于表4。
表1
表2
表3
表4
实施例的有益效果
本发明实施例所提供的隐形眼镜用组合物,其纳米金颗粒作为眼科产品在细胞毒指针性试验皆无细胞毒性,代表作为眼科产品具良好生物安全性,且其通过纳米金颗粒与辅助修护成分的配伍使用,能更好的发挥纳米金颗粒的使用效果,并能消除或舒缓长时间配戴隐形眼镜者眼睛的不适感和异物感等负面评价,与长时间维持眼睛于湿润与舒适的状态。经由眼角膜细胞修护实验可推论实验例对于日常眼角膜损伤修护确实优于比较例。
本发明的其中一有益效果在于,本发明的具有角膜修护功能的眼用产品,其能通过“眼用组合物包含多个纳米金颗粒以及至少一辅助修护成分,纳米金颗粒的有效浓度为0.01ppm至3000ppm”的技术特征,以预防和治疗日常角膜损伤,及减少如疼痛、畏光、流泪、模糊、血管增生等眼睛不适症状。
更进一步来说,纳米金颗粒至少具有抗氧化、抗发炎、抗敏舒缓、修护角膜及抑制血管增生等功能或作用;因此,本发明的眼用产品能有效维持眼睛的健康与舒适。再者,辅助修护成分可采用非酵素抗氧化剂,其与纳米金成分可以不同的机理协同运作,而产生预想不到的抗氧化效果。
更进一步来说,可在纳米金颗粒的表面修饰有至少一种功能性分子团,即功能性分子团附着于纳米金颗粒的表面上,以增强纳米金颗粒的抗氧化能力及增加纳米金颗粒的功能性。
以上所公开的内容仅为本发明的优选可行实施例,并非因此局限本发明的权利要求书的保护范围,所以凡是运用本发明说明书及附图内容所做的等效技术变化,均包含于本发明的权利要求书的保护范围内。
Claims (20)
1.一种具有角膜修护功能的眼用产品,其包括眼用组合物,其特征在于,所述眼用组合物包含多个纳米金颗粒以及至少一种辅助修护成分,所述纳米金颗粒的有效浓度为0.01ppm至3000ppm,所述辅助修护成分的含量,以所述眼用组合物的总量为100wt%计,为大于0且小于20wt%。
2.根据权利要求1所述的具有角膜修护功能的眼用产品,其特征在于,所述纳米金颗粒的平均粒径为0.01nm至100nm,且所述纳米金颗粒的有效浓度为0.05ppm至1600ppm,其中,所述辅助修护成分的含量为0.01wt%至5wt%。
3.根据权利要求2所述的具有角膜修护功能的眼用产品,其特征在于,所述纳米金颗粒的平均粒径为0.5nm至40nm,且所述纳米金颗粒的有效浓度为1ppm至400ppm,其中,所述辅助修护成分的含量为0.05wt%至3wt%。
4.根据权利要求1所述的具有角膜修护功能的眼用产品,其特征在于,所述纳米金颗粒的表面修饰有至少一种功能性分子团,所述功能性分子团选自亲水性官能基、含酚基的化合物、多醣类物质、含至少一个NH2基或COOH基的肽类物质及硫醇配体中的至少一种。
5.根据权利要求4所述的具有角膜修护功能的眼用产品,其特征在于,所述功能性分子团的含量,以所述眼用组合物的总量为100wt%计,为0.01wt%至5wt%。
6.根据权利要求4所述的具有角膜修护功能的眼用产品,其特征在于,所述亲水性官能基为OH基、CONH基、CONH2基或COOH基。
7.根据权利要求4所述的具有角膜修护功能的眼用产品,其特征在于,所述含酚基的化合物为单酚类化合物、多酚类化合物或黄酮类化合物。
8.根据权利要求4所述的具有角膜修护功能的眼用产品,其特征在于,所述多醣类物质为醣醛酸、甲基羧酸几丁质、甲基羧酸几丁聚醣、褐藻酸或透明质酸。
9.根据权利要求4所述的具有角膜修护功能的眼用产品,其特征在于,所述肽类物质的分子量为300道尔顿至300,000道尔顿。
10.根据权利要求4所述的具有角膜修护功能的眼用产品,其特征在于,所述硫醇配体为硫辛酸或二氢硫辛酸。
11.根据权利要求1所述的具有角膜修护功能的眼用产品,其特征在于,所述辅助修护成分选自硫酸软骨素、α-硫辛酸、2-氨基乙磺酸以及L-天门冬氨酸钾中的至少一种。
12.根据权利要求1所述的具有角膜修护功能的眼用产品,其特征在于,所述眼用组合物的pH值为6至8,且渗透压为240Osmol/Kg至400Osmol/Kg。
13.根据权利要求1所述的具有角膜修护功能的眼用产品,其特征在于,所述眼用组合物以溶液、凝胶或软膏的形式存在。
14.根据权利要求13所述的具有角膜修护功能的眼用产品,其特征在于,所述具有角膜修护功能的眼用产品还包括传递媒介,用于将所述眼用组合物传递至眼睛。
15.根据权利要求14所述的具有角膜修护功能的眼用产品,其特征在于,所述传递媒介为眼用基质或敷料。
16.根据权利要求13所述的具有角膜修护功能的眼用产品,其特征在于,所述具有角膜修护功能的眼用产品还包括隐形眼镜镜片,且所述隐形眼镜镜片浸泡于以溶液形式存在的所述眼用组合物中。
17.一种具有角膜修护功能的眼用产品,其包括眼用组合物,其特征在于,所述眼用组合物包含多个纳米金颗粒,所述纳米金颗粒的有效浓度为0.01ppm至3000ppm,所述纳米金颗粒的平均粒径为0.01nm至100nm。
18.根据权利要求17所述的具有角膜修护功能的眼用产品,其特征在于,所述纳米金颗粒的平均粒径为0.5nm至40nm。
19.根据权利要求17所述的具有角膜修护功能的眼用产品,其特征在于,所述纳米金颗粒的有效浓度为0.05ppm至1600ppm。
20.根据权利要求17所述的具有角膜修护功能的眼用产品,其特征在于,所述纳米金颗粒的有效浓度为1ppm至400ppm。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW108122577A TWI759610B (zh) | 2019-06-27 | 2019-06-27 | 具有角膜修護功能的眼用產品 |
TW108122577 | 2019-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112138022A true CN112138022A (zh) | 2020-12-29 |
Family
ID=71096550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010240704.1A Pending CN112138022A (zh) | 2019-06-27 | 2020-03-31 | 具有角膜修护功能的眼用产品 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20200405751A1 (zh) |
EP (1) | EP3756651A1 (zh) |
JP (1) | JP2021006519A (zh) |
CN (1) | CN112138022A (zh) |
TW (1) | TWI759610B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202000012535A1 (it) * | 2020-05-27 | 2021-11-27 | Stefano Colombo | Composizione oftalmica a base di acido ialuronico per la protezione dai danni causati dall’inquinamento ambientale |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018095429A1 (zh) * | 2016-11-28 | 2018-05-31 | 深圳深见医药科技有限公司 | 金团簇或含金团簇的物质在制备预防和/或治疗青光眼药物中的应用 |
CN109718376A (zh) * | 2017-10-27 | 2019-05-07 | 晶硕光学股份有限公司 | 具有抗敏舒缓效果的眼用产品 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8679859B2 (en) * | 2007-03-12 | 2014-03-25 | State of Oregon by and through the State Board of Higher Education on behalf of Porland State University | Method for functionalizing materials and devices comprising such materials |
WO2016077467A1 (en) * | 2014-11-11 | 2016-05-19 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
US10940206B2 (en) * | 2015-05-21 | 2021-03-09 | Ophtalmis Monaco | Ophthalmic composition comprising lipoic acid and a mucomimetic polymer |
EA037698B1 (ru) * | 2016-10-07 | 2021-05-12 | Брим Байотекнолоджи, Инк. | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение |
EP3626237B1 (en) * | 2017-05-15 | 2023-11-08 | Tsubota Laboratory, Inc. | Composition and functional food for preventing myopia |
JP2018203728A (ja) * | 2017-06-01 | 2018-12-27 | ロート製薬株式会社 | 視覚機能の再活性化用眼科組成物 |
WO2018235939A1 (ja) * | 2017-06-23 | 2018-12-27 | Tkヘルスリサーチ株式会社 | 包接化された抗酸化物質を含む眼科用組成物ならびにその使用 |
TWI651095B (zh) * | 2017-10-18 | 2019-02-21 | 晶碩光學股份有限公司 | 具有抗敏舒緩效果的眼用產品 |
WO2020147830A1 (en) * | 2019-01-19 | 2020-07-23 | Goldred Nanobiotech Co., Ltd. | Ocular lens, pharmaceutical composition, and uses thereof |
-
2019
- 2019-06-27 TW TW108122577A patent/TWI759610B/zh active
-
2020
- 2020-03-31 CN CN202010240704.1A patent/CN112138022A/zh active Pending
- 2020-06-08 JP JP2020099263A patent/JP2021006519A/ja active Pending
- 2020-06-10 US US16/897,408 patent/US20200405751A1/en not_active Abandoned
- 2020-06-15 EP EP20179945.9A patent/EP3756651A1/en active Pending
-
2023
- 2023-04-04 US US18/130,761 patent/US20230233602A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018095429A1 (zh) * | 2016-11-28 | 2018-05-31 | 深圳深见医药科技有限公司 | 金团簇或含金团簇的物质在制备预防和/或治疗青光眼药物中的应用 |
CN109718376A (zh) * | 2017-10-27 | 2019-05-07 | 晶硕光学股份有限公司 | 具有抗敏舒缓效果的眼用产品 |
Also Published As
Publication number | Publication date |
---|---|
US20200405751A1 (en) | 2020-12-31 |
JP2021006519A (ja) | 2021-01-21 |
TWI759610B (zh) | 2022-04-01 |
EP3756651A1 (en) | 2020-12-30 |
TW202100166A (zh) | 2021-01-01 |
US20230233602A1 (en) | 2023-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7432654B2 (ja) | 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法 | |
CN1281283C (zh) | 治疗和/或护理眼睛的方法和组合物 | |
US8648057B2 (en) | Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate and use of calcium chelating agent and ophthalmologically compatible viscosity regulator | |
CN111991415B (zh) | 一种眼部护理组合物及其制备方法和用途 | |
US20230301908A1 (en) | Contact lens product having antioxidative function | |
KR20200118426A (ko) | 근시 진행의 치료 | |
US20230233602A1 (en) | Contact lens product with cornea repair function | |
US9351990B2 (en) | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion | |
WO2015168140A1 (en) | Ophthalmic compositions and methods for treating eyes | |
CN109722347B (zh) | 一种含有黄原胶的保湿润滑组合物及其应用 | |
TWI798452B (zh) | 隱形眼鏡產品 | |
CN115068595A (zh) | 一种眼用抗辐射组合物及其制备方法与应用 | |
CN114748611A (zh) | 一种具有抗氧化保湿润滑作用的组合物及其应用 | |
CN113908171A (zh) | 一种眼用润滑液组合物及其应用 | |
EP3368006B1 (en) | Therapeutic use of a sterile aqueous ophthalmic solution | |
CN112426414B (zh) | 一种眼部抗黏连和防蓝光损伤的护理液及其制备方法 | |
CN113679666A (zh) | Ok镜用润滑液、预防和治疗近视的ok镜产品 | |
HALİLİ et al. | Comparison of Two Different Bandage Contact Lens Types Used After Corneal Crosslinking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |